A Novel Approach to Enhance True Recovery After Stroke

December 3, 2025 updated by: Danderyd Hospital

A Novel Approach to the Development of New Treatment Strategies to Enhance True Recovery After Stroke, Based on Laboratory Movement Analysis and Clinical Aspects of Gait Function and Walking

The purpose of this study is to elucidate pathophysiological mechanisms behind gait disturbances during the early recovery phase after hemiparetic stroke to identify targets for new treatment strategies.

Using an explorative, observational study design, pathophysiological mechanisms at play during the early recovery phase will be monitored, by repeated clinical assessments during inpatient rehabilitation as well as examinations of muscle activation patterns, kinematics of walking, corticospinal and reticulospinal function < 1 month, 3 and 6 months after hemiparetic stroke.

Inclusion: Eligible patients will have suffered a stroke, verified by CT or MRI examination and are admitted to inpatient care at the University Department of Rehabilitation Medicine Danderyd Hospital (RUDS). Thirty patients will be included consecutively. With an anticipated loss of 4-10 patients, at least 20 are expected to complete the study.

The clinical assessment protocols include standardized measures for the assessment of clinical and self-perceived aspects of functioning and disability. These assessments will be performed and repeated < 1 month, at 3 months and 6 months post-stroke by a therapist not responsible for rehabilitation interventions. At each of these assessment instances, laboratory movement analysis including electromyography (EMG) and ultrasound of the lower extremity muscle will be performed. In addition, a short assessment of body function and activity will be performed weekly during inpatient rehabilitation.

Study Overview

Status

Terminated

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

6

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Stockholm County
      • Danderyd, Stockholm County, Sweden, SE-18288
        • Department of Rehabilitation Medicine, Danderyd Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Eligible patients will have suffered a stroke, verified by CT or MRI examination and are admitted to inpatient care at the University Department of Rehabilitation Medicine Danderyd Hospital.

Description

Inclusion Criteria:

  • Participants with hemiplegia, dependence in ambulation (1- 4 according to the Functional Ambulation Categories (FAC)),
  • >= 50 points on the Trunk Control Test.
  • Impaired dorsiflexion manifested as impaired voluntarily dorsiflexion and inability to hold the ankle in a dorsiflexed position while sitting, and for ambulatory participants, impaired dorsiflexion during swing phase and initial contact during visual inspection of gait.
  • Recommended for an ancle foot orthosis (AFO) by an experienced physiotherapist. Able to understand study information and provide informed consent.

Exclusion Criteria:

  • Contracture that severely restricts gait movements in a lower limb joint,
  • cardiovascular or other somatic condition incompatible with intensive gait training,
  • notifiable infectious disease, contagious infections (e.g. MRSA or ESBL)
  • Inability to participate in the rehabilitation intervention due to behavioral or psychiatric disorder
  • when magnetic resonance imaging will be performed, additional exclusion criteria are current or history of epilepsy, metal implants in the brain/skull cochlear implants, any implanted neurostimulator, cardiac pacemaker or cardiac implants of metal and infusion device.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fugl-Meyer score (FMA-LE)
Time Frame: At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Assesses sensory and movement related functions in the lower extremity (0p max impairment summed up to 86p max no detected impairment)
At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Motion analysis during gait
Time Frame: At baseline, at 3 and 6 months to assess change.
In a movement laboratory (Vicon V16), data for motion analysis will be collected by assessing orientation of body segments and joint angle trajectories and forces by means of force plates (AMTI) during walking.
At baseline, at 3 and 6 months to assess change.
Electromyography (EMG)
Time Frame: At baseline, at 3 and 6 months to assess change.
EMG is used to measure muscle activation patterns during gait.
At baseline, at 3 and 6 months to assess change.
Modified Ashworth scale 0-5
Time Frame: At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Assesses spasticity on a 6 point scale/muscle (0p no impairment, 5p max impairment/muscle)
At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Passive range of motion in the lower extremity
Time Frame: At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Clinical assessment of range of motion with a goniometer
At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
The 10 meter walk test
Time Frame: At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Assesses gait speed
At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
6 minutes walk test
Time Frame: At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Assesses walking endurance in meters walked
At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Rated Perceived Exertion (RPE) Scale
Time Frame: At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Ratings (min 6, max 20) according to the RPE scale are made at the end of the 6 minutes walk test.
At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
The Functional Ambulation Categories (FAC)
Time Frame: At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Assesses independence in walking (0p nonfunctional, 5p independent) Total score 0-5p
At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
The Balance evaluation systems test (BEST-test)
Time Frame: At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Assesses postural control, incorporating bio-mechanical systems, limits of stability, anticipatory postural adjustment, automatic postural responses, sensory orientation, stability in gait (0p max impairment summed up to 108p no impairment)
At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Falls Efficacy Scale (FES-S)
Time Frame: At baseline and at 3 and 6 months to assess change.
Assesses self perceived balance in every day life activities rated on a 11 point scale (0p not safe at all 10p completely safe). Total score: 0- 130 p
At baseline and at 3 and 6 months to assess change.
The Montreal Cognitive Assessment (MoCa)
Time Frame: At baseline and at 3 and 6 months to assess change.
Assesses mental function (0p max impairment summed up to 30p no detected impairment)
At baseline and at 3 and 6 months to assess change.
National Institute of Health Stroke Scale
Time Frame: At baseline and at 3 and 6 months to assess change.
To assess overall effects of stroke (ranging from 0-44 points, a higher score indicating more severe disability).
At baseline and at 3 and 6 months to assess change.
Neuroflexor
Time Frame: At baseline, at 3 and 6 months to assess change.
Medical technology device. Assesses spasticity by identifying the neural, viscous and elastic components during passive movement using a biomechanical algorithm (presented in Newton)
At baseline, at 3 and 6 months to assess change.
Navigated Transcranial magnetic stimulation (nTMS)
Time Frame: At baseline and at 3 and 6 months to assess change.
To estimate the integrity of the corticospinal tract, transcraniel magnetic stimulation will be applied to the primary motor cortex and motor evoked potentials will be will be recorded from the lower leg muscles using electromyography.
At baseline and at 3 and 6 months to assess change.
Barthel Index
Time Frame: At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Assesses independence in mobility and personal care (0p dependent 10/15p independent) Total score 0-100p
At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Monofilament
Time Frame: At baseline, at 3 and 6 months to assess change.
Measuring cutaneous sensory perception threshold under foot with a pressure of 4, 6 and 10 grams.
At baseline, at 3 and 6 months to assess change.
Pain drawing
Time Frame: At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Self-assessed location and type of pain on the body
At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Numeric rating scale of pain
Time Frame: At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Self-rated general intensity of pain at time of assessment (0 no pain, 10 worst imaginable pain)
At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Medical Research Council scale
Time Frame: At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Assesses movement strength at a specific joint and motion (0 no muscle activity 5 normal force)
At baseline, weekly during inpatient rehab and at 3 and 6 months to assess change.
Walking impact scale (Walk-12)
Time Frame: At baseline and at 3 and 6 months to assess change
Measures rated limitations in walking activities (1 no limitation, 5 extreme limitation)
At baseline and at 3 and 6 months to assess change

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Susanne M Palmcrantz, PhD, Dep of Clinical Sciences, Karolinska Institutet

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 29, 2023

Primary Completion (Actual)

October 30, 2025

Study Completion (Actual)

October 30, 2025

Study Registration Dates

First Submitted

April 28, 2022

First Submitted That Met QC Criteria

April 28, 2022

First Posted (Actual)

May 3, 2022

Study Record Updates

Last Update Posted (Actual)

December 10, 2025

Last Update Submitted That Met QC Criteria

December 3, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Observational

Subscribe